Literature DB >> 21200143

Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Chenguang Wang1, Michael P Lisanti, D Joshua Liao.   

Abstract

The c-myc is a proto-oncogene that manifests aberrant expression at high frequencies in most types of human cancer. C-myc gene amplifications are often observed in various cancers as well. Ample studies have also proved that c-myc has a potent oncogenicity, which can be further enhanced by collaborations with other oncogenes such as Bcl-2 and activated Ras. Studies on the collaborations of c-myc with Ras or other genes in oncogenicity have established several basic concepts and have disclosed their underlying mechanisms of tumor biology, including "immortalization" and "transformation". In many cases, these collaborations may converge at the cyclin D1-CDK4 complex. In the meantime, however, many results from studies on the c-myc, Ras and cyclin D1-CDK4 also challenge these basic concepts of tumor biology and suggest to us that the immortalized status of cells should be emphasized. Stricter criteria and definitions for a malignantly transformed status and a benign status of cells in culture also need to be established to facilitate our study of the mechanisms for tumor formation and to better link up in vitro data with animal results and eventually with human cancer pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21200143      PMCID: PMC3048075          DOI: 10.4161/cc.10.1.14449

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  194 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

2.  Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

Authors:  Sabine Glöckner; Hilke Buurman; Wolfram Kleeberger; Ulrich Lehmann; Hans Kreipe
Journal:  Lab Invest       Date:  2002-10       Impact factor: 5.662

Review 3.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Authors:  Dennis W Stacey
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

4.  Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues.

Authors:  Maria De Falco; Valentina Fedele; Luca De Luca; Roberta Penta; Giuliano Cottone; Ivan Cavallotti; Vincenza Laforgia; Antonio De Luca
Journal:  J Anat       Date:  2004-11       Impact factor: 2.610

Review 5.  Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells.

Authors:  Paul Yaswen; Martha R Stampfer
Journal:  Int J Biochem Cell Biol       Date:  2002-11       Impact factor: 5.085

6.  Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.

Authors:  Chenguang Wang; Nagarajan Pattabiraman; Jian Nian Zhou; Maofu Fu; Toshiyuki Sakamaki; Chris Albanese; Zhiping Li; Kongming Wu; James Hulit; Peter Neumeister; Phyllis M Novikoff; Michael Brownlee; Philipp E Scherer; Joan G Jones; Kathleen D Whitney; Lawrence A Donehower; Emily L Harris; Thomas Rohan; David C Johns; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

7.  Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.

Authors:  Shamila Ahamed; James S Foster; Antonin Bukovsky; J Alan Diehl; Jay Wimalasena
Journal:  Mol Carcinog       Date:  2002-05       Impact factor: 4.784

8.  Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.

Authors:  Rumi Sasaki; Mako Narisawa-Saito; Takashi Yugawa; Masatoshi Fujita; Hironori Tashiro; Hidetaka Katabuchi; Tohru Kiyono
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

9.  Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice.

Authors:  Dezhong Joshua Liao; Yong Wang; Jiusheng Wu; Nazmi Volkan Adsay; David Grignon; Fayyaz Khanani; Fazlul H Sarkar
Journal:  J Carcinog       Date:  2006-07-05

10.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.

Authors:  Y Taya; K Hosogai; S Hirohashi; Y Shimosato; R Tsuchiya; N Tsuchida; M Fushimi; T Sekiya; S Nishimura
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

View more
  64 in total

Review 1.  Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

Authors:  Christopher C Mills; E A Kolb; Valerie B Sampson
Journal:  Cancer Res       Date:  2018-01-08       Impact factor: 12.701

2.  Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Authors:  Cassandra J Vandenberg; Paul Waring; Andreas Strasser; Suzanne Cory
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 3.  MYC leads the way.

Authors:  Niranjan Venkateswaran; Maralice Conacci-Sorrell
Journal:  Small GTPases       Date:  2017-11-25

Review 4.  The dual role of the X-linked FoxP3 gene in human cancers.

Authors:  Margaret Redpath; Bin Xu; Leon C van Kempen; Alan Spatz
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

5.  Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

Authors:  Ying Gu; Jiawei Zhang; Xiaoxiao Ma; Byung-Wook Kim; Hailong Wang; Jinfan Li; Yi Pan; Yang Xu; Lili Ding; Lu Yang; Chao Guo; Xiwei Wu; Jun Wu; Kirk Wu; Xiaoxian Gan; Gang Li; Ling Li; Stephen J Forman; Wing-Chung Chan; Rongzhen Xu; Wendong Huang
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

6.  APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway.

Authors:  Guihua Wang; Feng Wang; Weifeng Ding; Jingchun Wang; Rongrong Jing; Haiquan Li; Xudong Wang; Yueguo Wang; Shaoqing Ju; Huimin Wang
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

Review 7.  Potential roles of longan flower and seed extracts for anti-cancer.

Authors:  Chih-Cheng Lin; Yuan-Chiang Chung; Chih-Ping Hsu
Journal:  World J Exp Med       Date:  2012-08-20

8.  Cyclin-dependent kinase 4 may be expressed as multiple proteins and have functions that are independent of binding to CCND and RB and occur at the S and G 2/M phases of the cell cycle.

Authors:  Yuan Sun; Xiaomin Lou; Min Yang; Chengfu Yuan; Ling Ma; Bing-Kun Xie; Jian-Min Wu; Wei Yang; Steven Xj Shen; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2013-09-24       Impact factor: 4.534

9.  Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines.

Authors:  Jun-Qiang Qian; Pei Sun; Zhan-Yu Pan; Zhi-Zhong Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.

Authors:  Xiao Wang; Jian Wu; Yiwei Lin; Yi Zhu; Xianglai Xu; Xin Xu; Zhen Liang; Shiqi Li; Zhenghui Hu; Xiangyi Zheng; Liping Xie
Journal:  J Exp Clin Cancer Res       Date:  2014-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.